...
search icon
elvn-img

Enliven Therapeutics Inc. Share Price

ELVN
NSQ
$27.16
-$0.85
(-3.03%)
1D
Industry: Pharmaceuticals Sector: Health Care

Enliven Therapeutics Inc. Analyst Forecast

Enliven Therapeutics Inc. Share Price Chart

Enliven Therapeutics Inc. Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.66B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
458.01K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.14
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$13.3 L
$30.22 H
$27.16

About Enliven Therapeutics Inc., Common Stock

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado. more

Industry: PharmaceuticalsSector: Health Care

Enliven Therapeutics Inc. Stock Returns

Time FrameELVNSectorS&P500
1-Week Return0.63%0.91%2.13%
1-Month Return8.51%-0.72%-0.47%
3-Month Return33.79%2.24%1.29%
6-Month Return43.78%19.1%7.71%
1-Year Return23.17%7.15%14.7%
3-Year Return29.33%16.96%67.75%
5-Year Return-51.64%33.23%76.25%
10-Year Return-54.73%142.74%271.83%

Enliven Therapeutics Inc. Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue97.00K99.00K622.00K297.00K317.00K[{"date":"2020-12-31","value":15.59,"profit":true},{"date":"2021-12-31","value":15.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":47.75,"profit":true},{"date":"2024-12-31","value":50.96,"profit":true}]
Gross Profit(97.00K)(99.00K)(622.00K)(297.00K)(317.00K)[{"date":"2020-12-31","value":-9700000,"profit":false},{"date":"2021-12-31","value":-9900000,"profit":false},{"date":"2022-12-31","value":-62200000,"profit":false},{"date":"2023-12-31","value":-29700000,"profit":false},{"date":"2024-12-31","value":-31700000,"profit":false}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses9.32M24.76M38.79M83.53M104.55M[{"date":"2020-12-31","value":8.91,"profit":true},{"date":"2021-12-31","value":23.68,"profit":true},{"date":"2022-12-31","value":37.1,"profit":true},{"date":"2023-12-31","value":79.89,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(9.32M)(24.76M)(38.79M)(83.53M)(104.55M)[{"date":"2020-12-31","value":-931800000,"profit":false},{"date":"2021-12-31","value":-2476200000,"profit":false},{"date":"2022-12-31","value":-3879100000,"profit":false},{"date":"2023-12-31","value":-8352900000,"profit":false},{"date":"2024-12-31","value":-10455400000,"profit":false}]
Total Non-Operating Income/Expense(9.62M)44.00K2.26M23.91M30.65M[{"date":"2020-12-31","value":-31.37,"profit":false},{"date":"2021-12-31","value":0.14,"profit":true},{"date":"2022-12-31","value":7.37,"profit":true},{"date":"2023-12-31","value":78.01,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(18.97M)(24.74M)(37.66M)(71.58M)(88.79M)[{"date":"2020-12-31","value":-1896600000,"profit":false},{"date":"2021-12-31","value":-2474000000,"profit":false},{"date":"2022-12-31","value":-3766200000,"profit":false},{"date":"2023-12-31","value":-7158400000,"profit":false},{"date":"2024-12-31","value":-8879200000,"profit":false}]
Income Taxes(31.00K)(22.00K)88.00K1.30M232.00K[{"date":"2020-12-31","value":-2.38,"profit":false},{"date":"2021-12-31","value":-1.69,"profit":false},{"date":"2022-12-31","value":6.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":17.85,"profit":true}]
Income After Taxes(18.93M)(24.72M)(37.75M)(72.88M)(89.02M)[{"date":"2020-12-31","value":-1893500000,"profit":false},{"date":"2021-12-31","value":-2471800000,"profit":false},{"date":"2022-12-31","value":-3775000000,"profit":false},{"date":"2023-12-31","value":-7288400000,"profit":false},{"date":"2024-12-31","value":-8902400000,"profit":false}]
Income From Continuous Operations(18.97M)(24.74M)(37.66M)(71.58M)(89.02M)[{"date":"2020-12-31","value":-1896600000,"profit":false},{"date":"2021-12-31","value":-2474000000,"profit":false},{"date":"2022-12-31","value":-3766200000,"profit":false},{"date":"2023-12-31","value":-7158400000,"profit":false},{"date":"2024-12-31","value":-8902400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(18.97M)(24.74M)(37.66M)(71.58M)(89.02M)[{"date":"2020-12-31","value":-1896600000,"profit":false},{"date":"2021-12-31","value":-2474000000,"profit":false},{"date":"2022-12-31","value":-3766200000,"profit":false},{"date":"2023-12-31","value":-7158400000,"profit":false},{"date":"2024-12-31","value":-8902400000,"profit":false}]
EPS (Diluted)(24.72)(9.60)(3.51)(2.19)(1.89)[{"date":"2020-12-31","value":-2472,"profit":false},{"date":"2021-12-31","value":-960,"profit":false},{"date":"2022-12-31","value":-351,"profit":false},{"date":"2023-12-31","value":-219,"profit":false},{"date":"2024-12-31","value":-188.82,"profit":false}]

Enliven Therapeutics Inc. Ratios

Enliven Therapeutics Inc. Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

ELVN
Cash Ratio 32.60
Current Ratio 32.95

Enliven Therapeutics Inc. Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ELVN
ROA (LTM) -17.62%
ROE (LTM) -25.43%

Enliven Therapeutics Inc. Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ELVN
Debt Ratio Lower is generally better. Negative is bad. 0.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.97

Enliven Therapeutics Inc. Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ELVN
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 3.48
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Enliven Therapeutics Inc. share price today?

Enliven Therapeutics Inc. (ELVN) share price today is $27.16

Can Indians buy Enliven Therapeutics Inc. shares?

Yes, Indians can buy shares of Enliven Therapeutics Inc. (ELVN) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ELVN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Enliven Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Enliven Therapeutics Inc. (ELVN) via the Vested app. You can start investing in Enliven Therapeutics Inc. (ELVN) with a minimum investment of $1.

How to invest in Enliven Therapeutics Inc. shares from India?

You can invest in shares of Enliven Therapeutics Inc. (ELVN) via Vested in three simple steps:

  • Click on Sign Up or Invest in ELVN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Enliven Therapeutics Inc. shares
What is Enliven Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of Enliven Therapeutics Inc. (ELVN) is $30.22. The 52-week low price of Enliven Therapeutics Inc. (ELVN) is $13.3.

What is Enliven Therapeutics Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Enliven Therapeutics Inc. (ELVN) is

What is Enliven Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Enliven Therapeutics Inc. (ELVN) is 3.48

What is Enliven Therapeutics Inc. dividend yield?

The dividend yield of Enliven Therapeutics Inc. (ELVN) is 0.00%

What is the Market Cap of Enliven Therapeutics Inc.?

The market capitalization of Enliven Therapeutics Inc. (ELVN) is $1.66B

What is Enliven Therapeutics Inc.'s stock symbol?

The stock symbol (or ticker) of Enliven Therapeutics Inc. is ELVN

How Can Investors Use Enliven Therapeutics Inc. Share Price Data for Long-Term Investment Decisions?

Consider the share price of Enliven Therapeutics Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Enliven Therapeutics Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Enliven Therapeutics Inc. shares for Indian investors?

When investing in Enliven Therapeutics Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Enliven Therapeutics Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Enliven Therapeutics Inc. share price with other stocks in the same sector?

Rather than merely checking the share price of Enliven Therapeutics Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Enliven Therapeutics Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top